137 related articles for article (PubMed ID: 4008686)
1. Standardizing 8-methoxypsoralen plasma profiles by using an emulsion form.
Van Boven M; Roelandts R; Adriaens P; Daenens P; Degreef H; Kinget R
J Am Acad Dermatol; 1985 May; 12(5 Pt 1):822-7. PubMed ID: 4008686
[TBL] [Abstract][Full Text] [Related]
2. [8-Methoxypsoralen (8-MOP)-a new galenic form and its relation to 8-MOP serum levels (author's transl)].
Nitsche V; Raff M; Bardach H
Arch Dermatol Res; 1981; 271(1):11-7. PubMed ID: 7294879
[TBL] [Abstract][Full Text] [Related]
3. Microenema of 8-methoxypsoralen in photochemotherapy of psoriasis.
Siddiqui AH; Stolk L; Korthals Altes-Levij van Vinninghe HR; Kammeijer A; Cormane RH
Arch Dermatol Res; 1982; 273(3-4):219-23. PubMed ID: 7165351
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
Stolk LM; Siddiqui AH; Westerhof W; Cormane RH
Br J Dermatol; 1985 Apr; 112(4):469-73. PubMed ID: 3994922
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
Nørgaard M; Hueg B; Staberg B
Photodermatol; 1985 Aug; 2(4):252-6. PubMed ID: 3903679
[TBL] [Abstract][Full Text] [Related]
6. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
Hönigsmann H; Jaschke E; Gschnait F; Brenner W; Fritsch P; Wolff K
Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
[TBL] [Abstract][Full Text] [Related]
7. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
Tanew A; Ortel B; Rappersberger K; Hönigsmann H
J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of 8-methoxypsoralen in psoriatic patients receiving topical 8-methoxypsoralen.
Neild VS; Scott LV
Br J Dermatol; 1982 Feb; 106(2):199-203. PubMed ID: 7059510
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy.
Shephard SE; Langguth P; Panizzon RG
Photodermatol Photoimmunol Photomed; 2001 Feb; 17(1):11-21. PubMed ID: 11169171
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of 8-methoxypsoralen after bath-PUVA for psoriasis: relationship to disease severity.
Gómez MI; Azaña JM; Arranz I; Harto A; Ledo A
Br J Dermatol; 1995 Jul; 133(1):37-40. PubMed ID: 7669638
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of 8-methoxypsoralen and phototoxicity studies during PUVA treatment of psoriasis with meladinin tablets.
Thune P
Acta Derm Venereol; 1978; 58(2):149-51. PubMed ID: 76395
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of 8-methoxypsoralen determined by high-pressure liquid chromatography in psoriatic patients ingesting drug from two manufacturers.
Ljunggren B; Carter DM; Albert J; Reid T
J Invest Dermatol; 1980 Jan; 74(1):59-62. PubMed ID: 7351495
[TBL] [Abstract][Full Text] [Related]
13. 8-MOP plasma levels in PUVA problem cases with psoriasis.
Wagner G; Hofmann C; Busch U; Schmid J; Plewig G
Br J Dermatol; 1979 Sep; 101(3):285-92. PubMed ID: 508594
[TBL] [Abstract][Full Text] [Related]
14. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
Berg M; Ros AM
Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of 8-methoxypsoralen following PUVA-bath photochemotherapy.
von Kobyletzki G; Hoffmann K; Kerscher M; Altmeyer P
Photodermatol Photoimmunol Photomed; 1998; 14(3-4):136-8. PubMed ID: 9779504
[TBL] [Abstract][Full Text] [Related]
16. Photochemotherapy in psoriasis-clinical response and 8-MOP plasma concentrations at two dose levels.
Andrew E; Nilsen A; Thune P; Wiik I
Clin Exp Dermatol; 1981 Nov; 6(6):591-600. PubMed ID: 7042134
[No Abstract] [Full Text] [Related]
17. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment.
Sakuntabhai A; Diffey BL; Farr PM
Br J Dermatol; 1995 Dec; 133(6):919-23. PubMed ID: 8547045
[TBL] [Abstract][Full Text] [Related]
18. Dietary influences on 8-MOP plasma levels in PUVA patients with psoriasis.
Roelandts R; Van Boven M; Deheyn T; Vander Stichele G; Degreef H; Daenens P
Br J Dermatol; 1981 Nov; 105(5):569-72. PubMed ID: 7295571
[TBL] [Abstract][Full Text] [Related]
19. Rectal suppositories of 8-methoxsalen produce fewer gastrointestinal side effects than the oral formulation.
Bolognia JL; Freije L; Amici L; Dellostritto J; Gasparro FP
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):424-7. PubMed ID: 8784281
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum levels and clinical results of PUVA therapy with three different dosage forms of 8-methoxypsoralen.
Siddiqui AH; Stolk LM; Cormane RH
Arch Dermatol Res; 1984; 276(5):343-5. PubMed ID: 6486881
[No Abstract] [Full Text] [Related]
[Next] [New Search]
